Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary of Roivant Sciences Ltd. (ROIV), and Arbutus Biopharma Corporation (ABUS) to resolve patent litigation related to lipid nanoparticle (LNP) delivery technology used in its COVID-19 vaccine.
Under the agreement, Moderna will make a $950 million payment in July 2026. An additional $1.3 billion payment is contingent on a favorable appellate ruling regarding Section 1498 of U.S. law, which Moderna had argued shields certain government-contracted sales from patent liability.
As part of the settlement, Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications and a covenant not to sue on certain patents, ending all related litigation tied to Moderna's COVID-19 vaccine.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.